Tamoxifen prevents premalignant changes of breast, but not ovarian, cancer in rats at high risk for both diseases

Alison Ting, Bruce F. Kimler, Carol J. Fabian, Brian K. Petroff

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Women at increased risk for breast cancer are at increased risk for ovarian cancer as well, reflecting common risk factors and intertwined etiology of the two diseases. We previously developed a rat model of elevated breast and ovarian cancer risk, allowing evaluation of dual-target cancer prevention strategies. Tamoxifen, a Food and Drug Administration- approved breast cancer chemoprevention drug, has been shown to promote ovarian cysts in premenopausal women; however, the effect of tamoxifen on ovarian cancer risk is still controversial. In the current experiment, Fischer 344 rats (n = 8 per treatment group) received tamoxifen (TAM) or vehicle (control) in factorial combination with combined breast and ovarian carcinogen (17β-estradiol and 7,12 dimethylbenza[a]anthracene, respectively). Mammary and ovarian morphologies were normal in the control and TAM groups. Carcinogen (CARC) treatment induced mammary dysplasia with elevated cell proliferation and reduced estrogen receptor-α expression and promoted preneoplastic changes in the ovary. In the CARC + TAM group, tamoxifen reduced preneoplastic changes and proliferation rate in the mammary gland, but not in the ovary, compared with rats treated with carcinogen alone. Putative stem cell markers (Oct-4 and aldehyde dehydrogenase 1) were also elevated in the mammary tissue by carcinogen and this expansion of the stem cell population was not reversed by tamoxifen. Our study suggests that tamoxifen prevents early progression to mammary cancer but has no effect on ovarian cancer progression in this rat model.

Original languageEnglish (US)
Pages (from-to)546-553
Number of pages8
JournalCancer Prevention Research
Volume1
Issue number7
DOIs
StatePublished - Dec 2008
Externally publishedYes

Fingerprint

Tamoxifen
Ovarian Neoplasms
Breast
Carcinogens
Breast Neoplasms
Ovary
Stem Cells
Fibrocystic Breast Disease
Tissue Expansion
Ovarian Cysts
Inbred F344 Rats
Chemoprevention
United States Food and Drug Administration
Human Mammary Glands
Estrogen Receptors
Estradiol
Cell Proliferation
Control Groups
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Tamoxifen prevents premalignant changes of breast, but not ovarian, cancer in rats at high risk for both diseases. / Ting, Alison; Kimler, Bruce F.; Fabian, Carol J.; Petroff, Brian K.

In: Cancer Prevention Research, Vol. 1, No. 7, 12.2008, p. 546-553.

Research output: Contribution to journalArticle

Ting, Alison ; Kimler, Bruce F. ; Fabian, Carol J. ; Petroff, Brian K. / Tamoxifen prevents premalignant changes of breast, but not ovarian, cancer in rats at high risk for both diseases. In: Cancer Prevention Research. 2008 ; Vol. 1, No. 7. pp. 546-553.
@article{e071bdff65bd4171ac5d17bdf6d3e78b,
title = "Tamoxifen prevents premalignant changes of breast, but not ovarian, cancer in rats at high risk for both diseases",
abstract = "Women at increased risk for breast cancer are at increased risk for ovarian cancer as well, reflecting common risk factors and intertwined etiology of the two diseases. We previously developed a rat model of elevated breast and ovarian cancer risk, allowing evaluation of dual-target cancer prevention strategies. Tamoxifen, a Food and Drug Administration- approved breast cancer chemoprevention drug, has been shown to promote ovarian cysts in premenopausal women; however, the effect of tamoxifen on ovarian cancer risk is still controversial. In the current experiment, Fischer 344 rats (n = 8 per treatment group) received tamoxifen (TAM) or vehicle (control) in factorial combination with combined breast and ovarian carcinogen (17β-estradiol and 7,12 dimethylbenza[a]anthracene, respectively). Mammary and ovarian morphologies were normal in the control and TAM groups. Carcinogen (CARC) treatment induced mammary dysplasia with elevated cell proliferation and reduced estrogen receptor-α expression and promoted preneoplastic changes in the ovary. In the CARC + TAM group, tamoxifen reduced preneoplastic changes and proliferation rate in the mammary gland, but not in the ovary, compared with rats treated with carcinogen alone. Putative stem cell markers (Oct-4 and aldehyde dehydrogenase 1) were also elevated in the mammary tissue by carcinogen and this expansion of the stem cell population was not reversed by tamoxifen. Our study suggests that tamoxifen prevents early progression to mammary cancer but has no effect on ovarian cancer progression in this rat model.",
author = "Alison Ting and Kimler, {Bruce F.} and Fabian, {Carol J.} and Petroff, {Brian K.}",
year = "2008",
month = "12",
doi = "10.1158/1940-6207.CAPR-08-0015",
language = "English (US)",
volume = "1",
pages = "546--553",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Tamoxifen prevents premalignant changes of breast, but not ovarian, cancer in rats at high risk for both diseases

AU - Ting, Alison

AU - Kimler, Bruce F.

AU - Fabian, Carol J.

AU - Petroff, Brian K.

PY - 2008/12

Y1 - 2008/12

N2 - Women at increased risk for breast cancer are at increased risk for ovarian cancer as well, reflecting common risk factors and intertwined etiology of the two diseases. We previously developed a rat model of elevated breast and ovarian cancer risk, allowing evaluation of dual-target cancer prevention strategies. Tamoxifen, a Food and Drug Administration- approved breast cancer chemoprevention drug, has been shown to promote ovarian cysts in premenopausal women; however, the effect of tamoxifen on ovarian cancer risk is still controversial. In the current experiment, Fischer 344 rats (n = 8 per treatment group) received tamoxifen (TAM) or vehicle (control) in factorial combination with combined breast and ovarian carcinogen (17β-estradiol and 7,12 dimethylbenza[a]anthracene, respectively). Mammary and ovarian morphologies were normal in the control and TAM groups. Carcinogen (CARC) treatment induced mammary dysplasia with elevated cell proliferation and reduced estrogen receptor-α expression and promoted preneoplastic changes in the ovary. In the CARC + TAM group, tamoxifen reduced preneoplastic changes and proliferation rate in the mammary gland, but not in the ovary, compared with rats treated with carcinogen alone. Putative stem cell markers (Oct-4 and aldehyde dehydrogenase 1) were also elevated in the mammary tissue by carcinogen and this expansion of the stem cell population was not reversed by tamoxifen. Our study suggests that tamoxifen prevents early progression to mammary cancer but has no effect on ovarian cancer progression in this rat model.

AB - Women at increased risk for breast cancer are at increased risk for ovarian cancer as well, reflecting common risk factors and intertwined etiology of the two diseases. We previously developed a rat model of elevated breast and ovarian cancer risk, allowing evaluation of dual-target cancer prevention strategies. Tamoxifen, a Food and Drug Administration- approved breast cancer chemoprevention drug, has been shown to promote ovarian cysts in premenopausal women; however, the effect of tamoxifen on ovarian cancer risk is still controversial. In the current experiment, Fischer 344 rats (n = 8 per treatment group) received tamoxifen (TAM) or vehicle (control) in factorial combination with combined breast and ovarian carcinogen (17β-estradiol and 7,12 dimethylbenza[a]anthracene, respectively). Mammary and ovarian morphologies were normal in the control and TAM groups. Carcinogen (CARC) treatment induced mammary dysplasia with elevated cell proliferation and reduced estrogen receptor-α expression and promoted preneoplastic changes in the ovary. In the CARC + TAM group, tamoxifen reduced preneoplastic changes and proliferation rate in the mammary gland, but not in the ovary, compared with rats treated with carcinogen alone. Putative stem cell markers (Oct-4 and aldehyde dehydrogenase 1) were also elevated in the mammary tissue by carcinogen and this expansion of the stem cell population was not reversed by tamoxifen. Our study suggests that tamoxifen prevents early progression to mammary cancer but has no effect on ovarian cancer progression in this rat model.

UR - http://www.scopus.com/inward/record.url?scp=62349108502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62349108502&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-08-0015

DO - 10.1158/1940-6207.CAPR-08-0015

M3 - Article

VL - 1

SP - 546

EP - 553

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 7

ER -